Tag Archive for: Awakn Life Sciences
https://psychedelicspotlight.com/wp-content/uploads/2022/07/Company_Press_Releases_TemplateArtboard-1-2.jpg 875 1310 James Hallifax https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png James Hallifax2022-07-22 17:33:112022-07-22 17:33:11A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialBusiness, Stock Reports
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
https://psychedelicspotlight.com/wp-content/uploads/2022/05/Elon_Musk_Tweets_Psychedelics_CEOs_Swarm_Psychedelic_Spotlight.jpg 802 1200 James Hallifax https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png James Hallifax2022-05-02 18:22:442022-06-08 13:33:36Elon Musk Excites Psychedelic Industry CEOs with This Tweet
Elon Musk Excites Psychedelic Industry CEOs with This TweetBusiness, News
This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
https://psychedelicspotlight.com/wp-content/uploads/2022/03/5_Most_Important_Psychedelic_Clinical_Trials_2022_Psychedelic_Spotlight.jpg 802 1200 James Hallifax https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png James Hallifax2022-03-30 16:56:512022-03-30 16:57:565 Most Important Psychedelic Clinical Trials in 2022
5 Most Important Psychedelic Clinical Trials in 2022Research
Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
https://psychedelicspotlight.com/wp-content/uploads/2022/01/Ketamine_Trial_Alcohol_Use_Disorder_Promising_Results_Awakn_Life_Sciences_Psychedelic_Spotlight.jpg 875 1310 Travis Reilly https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Travis Reilly2022-01-12 15:12:092022-01-12 15:12:10Ketamine Trial for Alcohol Use Disorder Delivers Very Promising Results
Ketamine Trial for Alcohol Use Disorder Delivers Very Promising ResultsTreatment
Awakn Life Sciences' Head of Ketamine-Assisted Therapy, Professor Celia Morgan, says world’s first controlled trial to investigate efficacy of ketamine-assisted therapy for treatment of Alcohol Use Disorder "paves the way for a paradigm shift."
https://psychedelicspotlight.com/wp-content/uploads/2022/01/Psychedelic_Business_Spotlight_Mindset_Pharma_Awakn_Life_Sciences_Levitee_Labs_Field_Trip_Health_Psychedelic_Spotlight.jpg 962 1920 Travis Reilly https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Travis Reilly2022-01-07 18:17:452022-06-07 23:16:55Psychedelic Business Spotlight — January 7
Psychedelic Business Spotlight — January 7Business, Stock Reports
This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life Sciences explores behavioral addictions; Ei.Ventures buys virtual land for psychedelic therapy.
https://psychedelicspotlight.com/wp-content/uploads/2021/11/Psychedelic_Business_Spotlight_Novamind_Awakn_Life_Sciences_MIndMed_Red_Light_Holland_Way2Grow_Mycotopia_Psychedelic_Spotlight-1.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-11-19 17:38:472022-06-07 23:23:17Psychedelic Business Spotlight: November 19
Psychedelic Business Spotlight: November 19Business, Stock Reports
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
https://psychedelicspotlight.com/wp-content/uploads/2021/10/Psychedelic_Spotlight_Business_Roundup_October_29_Cybin_Mindcure_MindMed_Silo_Awakn_Mydecine.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-10-29 16:39:312022-06-07 23:23:46Psychedelic Business Spotlight: October 29
Psychedelic Business Spotlight: October 29Business, Stock Reports
This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
https://psychedelicspotlight.com/wp-content/uploads/2021/09/Psychedelic_Business_Spotlight_September-17.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-09-17 17:08:242022-06-07 23:24:40Psychedelic Business Spotlight: September 17, 2021
Psychedelic Business Spotlight: September 17, 2021Business, Stock Reports
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
https://psychedelicspotlight.com/wp-content/uploads/2021/07/Anthony-Tennison.jpeg 667 1000 Greg Gilman https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Greg Gilman2021-07-13 19:48:382021-08-18 01:40:38Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction
Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat AddictionBusiness, Research, Treatment
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about."
https://psychedelicspotlight.com/wp-content/uploads/2021/03/treatment-psychedelic-spotlight.jpg 667 1000 Jennifer Walker-Journey https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Jennifer Walker-Journey2021-03-16 16:54:572021-08-18 01:41:59U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction
U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for AddictionResearch
Awakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol use disorder.